CLICK HERE FOR BRIUMVI^® (ublituximab-xiiy) PRESCRIBING INFORMATION

A Bold
Approach

The PI3K Delta Inhibitor TGR-1202 In Combination with Brentuximab Vedotin (SGN-35) Synergistically Induces G2/M Phase Arrest and Cell Death Via Inhibition of Tubulin Polymerization in Hodgkin Lymphoma Cell Lines.

Started April 9, 2014 381

Read more

The PI3K Delta Inhibitor TGR-1202 Induces Cytotoxicity and Inhibits Phosphorylation of AKT in 17p Deleted and Non-17p Deleted CLL Cells in Vitro.

Started April 9, 2014 276

Read more

A Phase I Dose Escalation Study of TGR-1202, a Novel PI3K-d Inhibitor, For Patients with Relapsed or Refractory Hematologic Malignancies.

Started December 10, 2013 257

Read more

The PI3K-d Inhibitor TGR-1202 in Combination with Brentuximab Vedotin (SGN-35) Synergistically Induces G2/M Phase Arrest and Cell Death Via Inhibition Of Tubulin Polymerization in Hodgkin Lymphoma Cell Lines.

Started December 10, 2013 288

Read more

The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib are Highly Synergistic in Killing Human B- and T-Cell Lymphoma Cells.

Started December 10, 2013 352

Read more

The PI3k-delta inhibitor TGR-1202 induces cytotoxicity and inhibits phosphorylation of AKT in 17p deleted and non-17p deleted CLL cells in vitro.

Started September 9, 2013 309

Read more

A Novel, PI3K-Delta Specific Inhibitor in Multiple Myeloma.

Started June 14, 2013 423

Read more

Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal for Rituximab Relapsed/Refractory B-cell Malignancies.

Started June 14, 2013 378

Read more

Final Results of a Multicenter Phase Ib Single Agent Study with the Novel Anti-CD20 Monoclonal Antibody Ublituximab (TG-1101) in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL).

Started June 4, 2013 226

Read more

A Phase I Dose-Escalation Trial of Ublituximab (TG-1101), a Novel Anti-CD20 Monoclonal Antibody (mAb) for Rituximab Relapsed and/or Refractory C-Cell Lymphoma Patients.

Started June 2, 2013 266

Read more

Novel PI3K Inhibitors Demonstrate Marked Cytotoxicity in Models of T-Cell Lymphoma, Caused Apoptosis and Were Synergistic with the Novel Anti-CD20 Monoclonal Antibody Ublituximab in Models of B-Cell Lymphoma

Started June 1, 2013 271

Read more

Combined Carfilzomib and Selective PI3K-d Inhibition (TGR-1202) Results in Enhanced Myeloma Cell Apoptosis.

Started March 10, 2013 287

Read more